MIDDLE EAST AND ASIA INJECTABLE DRUGS MARKET ANALYSIS

To achieve a therapeutic effect in humans and animals, drug delivery is the method of delivering a pharmaceutical compound. Nasal and pulmonary routes are gaining increasing importance of drug delivery for the treatment on humans. For peptide and protein therapeutics these routes of drug delivery provide promising alternative to parenteral drug delivery.

The use of injectable drug delivery with advent of self-injection devices such as auto-injectors, pen-injectors, has made administration of drugs easy for patients at home without any medical assistance.

Figure 1. Middle East and Asia Injectable Drugs Market Value (US$ Mn), By Product Type, 2021

To learn more about this report, request sample copy

Figure 1.1 Middle East and Asia Injectable Drugs Market Value (US$ Mn), By Product Type, 2028

To learn more about this report, request sample copy

Figure 2. Middle East and Asia Injectable Drugs Market Value (US$ Mn), By Route of Administration, 2021

To learn more about this report, request sample copy

Figure 2.1. Middle East and Asia Injectable Drugs Market Value (US$ Mn), By Route of Administration, 2028

To learn more about this report, request sample copy

Middle East and Asia Injectable Drugs Market – Impact of Coronavirus (COVID-19) Pandemic

Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19 as pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 3.3 million new cases were reported, across the globe.

The COVID-19 pandemic and lockdown in various countries across the globe has negatively impacted the financial status of businesses across all sectors. Likewise, COVID-19 pandemic is expected to have a negative impact on Middle East and Asia injectable drugs market

Even if the COVID-19 pandemic has caused a huge disruption in global pharmaceutical supply chain, in Saudi COVID-19 impact was largely manageable in healthcare institutions. There are various reasons that can attribute between the effective exchange programs within the hospitals and huge increase in public healthcare such as technological advancements, ageing populations, changing disease patterns.

Middle East and Asia Injectable Drugs Market - Restraint

In Middle East, the diseases which are non-communicable are causing premature deaths such as heart disease (45%) and stroke (36%). The growing burden of non-communicable diseases in the region is increasing because of improper diet, smoking, high B.P., and huge body mass.

The market forces are to be taken over because of government failure to provide comprehensive healthcare services. So this has changed it in a commodity with curative impact rather than just preventive. The development of health systems had been driven by economic opportunities for providers.  

Key Players

Major players operating in the Middle East and Asia Injectable Drugs Market include Kalbe Farma, Takeda pharmaceuticals Co. Ltd., Livzon Pharmaceutical Group, Inc., Sun Pharmaceutical Industries, Ltd., Pfizer, Inc., Sanofi, Novartis, Tabuk, Novo Nordisk, GlaxoSmithKline plc, AstraZeneca, and Gerresheimer AG